Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility

References

• Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:625434.
   Web of Science ®Google Scholar
• Spitzer M, Huang G, Basaria S, et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long‒acting testosterone undecanoate improves sexual function and quality‒of‒life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10(6):1612–1627.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–856.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–733.
   PubMed Web of Science ®Google Scholar
• Fink JE, Hackney AC, Matsumoto M, et al. Mobility and biomechanical functions in the aging male: testosterone and the locomotive syndrome. Aging Male. 2018;1–8. DOI:10.1080/13685538.2018.1504914
   PubMedGoogle Scholar
• Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427.
   PubMedGoogle Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New Engl J Med. 2004;350(5):482–492.
   PubMed Web of Science ®Google Scholar
• McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18(3):373.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zong H, Yan H, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–1261.
   PubMedGoogle Scholar
• Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–644.
   PubMed Web of Science ®Google Scholar
• Wenker EP, Dupree JM, Langille GM, et al. The use of HCG‐based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med. 2015;12(6):1334–1337.
   PubMed Web of Science ®Google Scholar
• Clavijo RI, Hsiao W. Update on male reproductive endocrinology. Transl Androl Urol. 2018;7(Suppl 3):S367.
   PubMedGoogle Scholar
• La Vignera S, Condorelli RA, Cimino L, et al. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2016;19(1):34–39.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European academy of andrology (EAA) guidelines* on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8:970–987.
   Web of Science ®Google Scholar
• Nwabuobi C, Arlier S, Schatz F, et al. hCG: biological functions and clinical applications. Int J Molec Sci. 2017;18(10):2037.
   Web of Science ®Google Scholar
• Riccetti L, De Pascali F, Gilioli L, et al. Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro. Reprod Biol Endocrinol. 2017;15(1):1–12.
   PubMedGoogle Scholar
• Behre HM. Clinical use of FSH in male infertility. Front Endocrinol. 2019;10:322.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Duca Y, et al. FSH therapy for idiopathic male infertility: four schemes are better than one. Aging Male. 2019;1–6.
   PubMed Web of Science ®Google Scholar
• Bayram F, Elbuken G, Korkmaz C, et al. The effects of gonadotropin replacement therapy on metabolic parameters and body composition in men with idiopathic hypogonadotropic hypogonadism. Hormone Metab Res. 2016;48(2):112–117.
   PubMed Web of Science ®Google Scholar
• Buvat J, Lemaire A, Erbaut MB. Human chorionic gonadotropin treatment of nonorganic erectile failure and lack of sexual desire: a double-blind study. Urology. 1987;30(3):216–219.
   PubMed Web of Science ®Google Scholar
• Crosnoe LE, Grober E, Ohl D, et al. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2(2):106.
   PubMedGoogle Scholar
• Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metabol. 2005;90(5):2595–2602.
   PubMed Web of Science ®Google Scholar
• Roth M, Page S, Lin K, et al. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metabol. 2010;95(8):3806–3813.
   PubMed Web of Science ®Google Scholar
• Vicari E, Mongioi A, Calogero A, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism‐long‐term follow‐up. Int J Androl. 1992;15(4):320–329.
   PubMedGoogle Scholar
• Bauman WA, La Fountaine MF, Cirnigliaro CM, et al. Testicular responses to hCG stimulation at varying doses in men with spinal cord injury. Spinal Cord. 2017;55(7):659.
   PubMed Web of Science ®Google Scholar
• Repcekova D, Mikulaj L. Plasma testosterone response to HCG in normal men without and after administration of anabolic drug. Endokrinologie. 1977;69(1):115–118.
   PubMedGoogle Scholar
• Kohn TP, Louis MR, Pickett SM, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351–357. e1.
   PubMed Web of Science ®Google Scholar
• Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. 2009;92(2):594–604.
   PubMed Web of Science ®Google Scholar
• Anderson R, Wu F. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metabol. 1996;81(3):896–901.
   PubMed Web of Science ®Google Scholar
• Zhang GY, Gu YQ, Wang XH, et al. Pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 1998;19(6):761–768.
   PubMedGoogle Scholar
• Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel®. Biopharm Drug Dispos. 2003;24(3):115–120.
   PubMed Web of Science ®Google Scholar
• Chan CC, Ng EH, Chan MM, et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non‐obese women. Hum Reprod. 2003;18(11):2294–2297.
   PubMed Web of Science ®Google Scholar
• Weissinan A, Lurie S, Zalel Y, et al. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecol Endocrinol. 1996;10(4):273–276.
   PubMed Web of Science ®Google Scholar
• Saal W, Glowania H-J, Hengst W, et al. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. Fertil Steril. 1991;56(2):225–229.
   PubMed Web of Science ®Google Scholar
• Meier C, Christ-Crain M, Christoffel-Courtin C, et al. Serum estradiol after single dose hCG administration correlates with Leydig cell reserve in hypogonadal men: reassessment of the hCG stimulation test. Clin Lab. 2005;51(9–10):509–516.
   PubMed Web of Science ®Google Scholar